Cosmo Pharmaceuticals N.V.

LSE:0RGI Stock Report

Market Cap: CHF 982.0m

Cosmo Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Giovanni Di Napoli

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Giovanni Di Napoli (50 yo)

less than a year

Tenure

Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...

Leadership Team

NamePositionTenureCompensationOwnership
Alessandro Della Cha
Executive Chairman18.9yrs€1.16mno data
Niall Donnelly
Executive VP of Corporate Governanceless than a yearno datano data
Giovanni Di Napoli
Chief Executive Officer & Directorless than a yearno datano data
Mauro Ajani
Founder & Non-Executive Director18.9yrs€400.00kno data
Svetlana Sigalova
Chief Financial Officerless than a yearno datano data
Marco Lecchi
Chief Operating Officer3.9yrsno datano data
Davide Malavasi
Qualified Person & Technical Director13.3yrsno datano data
Luigi Longo
Chief Scientific Officer2.7yrsno datano data
Hazel Winchester
Head of Investor Relations2.9yrsno datano data
Biagio Vigano
Chief People Officer3.9yrsno datano data
Roberto Villa
Chief Manufacturing Officer27.9yrsno datano data
Ngo Nhan
President of Cosmo Intelligent Medical Devicesno datano datano data

2.9yrs

Average Tenure

52yo

Average Age

Experienced Management: 0RGI's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alessandro Della Cha
Executive Chairman18.9yrs€1.16mno data
Niall Donnelly
Executive VP of Corporate Governanceless than a yearno datano data
Giovanni Di Napoli
Chief Executive Officer & Directorless than a yearno datano data
Mauro Ajani
Founder & Non-Executive Director18.9yrs€400.00kno data
William Sandborn
Member of Scientific Advisory Boardno datano datano data
Geert D'Haens
Member of Scientific Advisory Boardno datano datano data
Silvio Danese
Member of Scientific Advisory Boardno datano datano data
Maria Roncarolo
Non-Executive Director12.7yrs€128.79kno data
Ralf Kiesslich
Member of Scientific Advisory Boardno datano datano data
Robert Steffen
Member of Scientific Advisory Boardno datano datano data
Silvana Perretta
Non-Executive Directorless than a yearno datano data
John O'Dea
Non-Executive Directorless than a yearno datano data

0.6yrs

Average Tenure

61yo

Average Age

Experienced Board: 0RGI's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 14:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Silvia SchanzBank Vontobel AG
Laura HindleyBerenberg